PE20071057A1 - Derivados de sulfonamidoanilina como inhibidores de cinasas janus - Google Patents

Derivados de sulfonamidoanilina como inhibidores de cinasas janus

Info

Publication number
PE20071057A1
PE20071057A1 PE2006001667A PE2006001667A PE20071057A1 PE 20071057 A1 PE20071057 A1 PE 20071057A1 PE 2006001667 A PE2006001667 A PE 2006001667A PE 2006001667 A PE2006001667 A PE 2006001667A PE 20071057 A1 PE20071057 A1 PE 20071057A1
Authority
PE
Peru
Prior art keywords
sulfonamidoaniline
metansulphonamide
ilamino
purin
derivatives
Prior art date
Application number
PE2006001667A
Other languages
English (en)
Inventor
Hans-Georg Capraro
Bernard Coupez
Pascal Furet
Paul W Manley
Soldermann Carole Pissot
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20071057A1 publication Critical patent/PE20071057A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

REFERIDA A UN DERIVADO DE SULFONAMIDOANILINA DE FORMULA (I), DONDE A ES N O CH; W, X, Y Y Z SON CH; R1 ES NR4R5 U OR4; R4 ES ALQUILO, CICLOALQUILO, ARILO, ENTRE OTROS; R5 ES H, ALQUILO, ENTRE OTROS; R2 ES H, ALQUILO, ALQUENILO C1-C7; R3 ES ALQUILO, ALQUENILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[3-(6-CICLOBUTILAMINO-9H-PURIN-2-ILAMINO)-FENIL]-METANSULFONAMIDA, N-[3-(6-ISOPROPILAMINO-9H-PURIN-2-ILAMINO)-FENIL]-METANSULFONAMIDA, N-{3-[6-((S)-2-HIDROXIMETIL-PIRROLIDIN-1-IL)-9H-PURIN-2-ILAMINO]-FENIL}-METANSULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE TIROSINA-CINASAS DE JANUS TALES COMO JAK-2 Y JAK-3 Y SON UTILES COMO AGENTES INMUNOSUPRESORES ASI COMO EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS
PE2006001667A 2005-12-22 2006-12-20 Derivados de sulfonamidoanilina como inhibidores de cinasas janus PE20071057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0526246.4A GB0526246D0 (en) 2005-12-22 2005-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
PE20071057A1 true PE20071057A1 (es) 2007-11-27

Family

ID=35841070

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001667A PE20071057A1 (es) 2005-12-22 2006-12-20 Derivados de sulfonamidoanilina como inhibidores de cinasas janus

Country Status (14)

Country Link
US (1) US20080261973A1 (es)
EP (1) EP1966210A2 (es)
JP (1) JP2009520725A (es)
KR (1) KR20080081177A (es)
CN (1) CN101331133A (es)
AR (1) AR058699A1 (es)
AU (1) AU2006328948B2 (es)
BR (1) BRPI0620449A2 (es)
CA (1) CA2631721A1 (es)
GB (1) GB0526246D0 (es)
PE (1) PE20071057A1 (es)
RU (1) RU2008129379A (es)
TW (1) TW200745113A (es)
WO (1) WO2007071393A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
EP2134723B1 (en) 2007-03-07 2017-07-12 Boehringer Ingelheim International GmbH 2,6 diamino-9h-purine derivatives and their use in the treatment of proliferative diseases
BRPI0809992A2 (pt) * 2007-04-02 2014-10-14 Palau Pharma Sa Derivados de pirrolopirimidina
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
KR101098335B1 (ko) * 2008-07-18 2011-12-26 성균관대학교산학협력단 신코나 기재 이작용성 유기 촉매 및 이를 이용한 메소-고리산무수물의 비대칭 고리 열림 반응을 통한 키랄성헤미에스터의 제조방법
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
AR073397A1 (es) * 2008-09-23 2010-11-03 Palau Pharma Sa Derivados de (r) -3- (n,n-dimetilamino) pirrolidina
CA2754890C (en) * 2009-03-13 2018-01-16 Piet Herdewijn Bicyclic heterocycles
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EA022488B1 (ru) * 2009-09-03 2016-01-29 Бристол-Майерс Сквибб Кампани Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011120911A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
US8889684B2 (en) * 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
BR112014012396B1 (pt) 2011-11-23 2020-08-25 Portola Pharmaceuticals, Inc inibidores de pirazina quinase, composição, método in vitro para inibição de quinase syk ou via de transdução de sinal, uso dos referidos inibidores e kit
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
EP2802568A1 (en) 2012-01-13 2014-11-19 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents.
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
MY173845A (en) * 2012-07-17 2020-02-24 Glaxosmithkline Ip No 2 Ltd Indolecarbonitriles as selective androgen receptor modulators
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
DK2958921T3 (da) * 2013-02-22 2017-11-06 Pfizer Pyrrolo[2,3-D]pyrimidin-derivater som hæmmere af Janus kinaser (JAK)
JP6564771B2 (ja) 2013-07-11 2019-08-21 エイシア バイオサイエンシーズ インコーポレイテッド キナーゼ阻害剤としてのピリミジン誘導体
KR102339228B1 (ko) 2013-08-23 2021-12-13 뉴파마, 인크. 특정 화학 물질, 조성물, 및 방법
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
EP4115882A1 (en) 2015-01-16 2023-01-11 The General Hospital Corporation Compounds for improving mrna splicing
EP3778605A3 (en) 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
CN107949388B (zh) 2015-10-09 2021-10-26 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
CN110300590A (zh) * 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN111212837A (zh) 2017-04-07 2020-05-29 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
CN112010789A (zh) * 2019-05-31 2020-12-01 中国科学院上海药物研究所 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
TW200800215A (en) * 2005-10-13 2008-01-01 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
TW200745113A (en) 2007-12-16
KR20080081177A (ko) 2008-09-08
AR058699A1 (es) 2008-02-20
CA2631721A1 (en) 2007-06-28
US20080261973A1 (en) 2008-10-23
JP2009520725A (ja) 2009-05-28
EP1966210A2 (en) 2008-09-10
AU2006328948A1 (en) 2007-06-28
RU2008129379A (ru) 2010-01-27
GB0526246D0 (en) 2006-02-01
CN101331133A (zh) 2008-12-24
WO2007071393A3 (en) 2007-07-26
BRPI0620449A2 (pt) 2011-11-08
AU2006328948B2 (en) 2009-10-22
WO2007071393A2 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
PE20071057A1 (es) Derivados de sulfonamidoanilina como inhibidores de cinasas janus
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
TW200517109A (en) Substituted pyridinones
PE20091712A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
MXPA05010621A (es) Pirimidinonas sustituidas.
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
UY29633A1 (es) Derivados de oxindol
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
GT200600105A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
SE0301446D0 (sv) New Compounds
DE602006018359D1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
PE20060868A1 (es) Sales de aminio de 1,2,3- triazoles como profarmacos que incluyen agentes antivirales
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины

Legal Events

Date Code Title Description
FD Application declared void or lapsed